Related references
Note: Only part of the references are listed.A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer
N. A. Nixon et al.
EUROPEAN JOURNAL OF CANCER (2018)
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer
C. Fribbens et al.
ANNALS OF ONCOLOGY (2018)
Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts
Jacqueline A. Shaw et al.
CLINICAL CANCER RESEARCH (2017)
Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer
Karen Page et al.
CLINICAL CHEMISTRY (2017)
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
M. J. Duffy et al.
EUROPEAN JOURNAL OF CANCER (2017)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Jose Baselga et al.
LANCET ONCOLOGY (2017)
HER2-positive breast cancer is lost in translation: time for patient-centered research
Isabelle Gingras et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer
Virginia G. Kaklamani et al.
ONCOLOGIST (2017)
Current Methods of the Circulating Tumor Cells (CTC) Analysis: A Brief Overview
Natalia Dementeva et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom?
Francesco Schettini et al.
BREAST CARE (2017)
CDK4/6 inhibition in early and metastatic breast cancer: A review
A. F. de Groot et al.
CANCER TREATMENT REVIEWS (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Validated biomarkers: The key to precision treatment in patients with breast cancer
Michael J. Duffy et al.
BREAST (2016)
Circulating tumor cells in breast cancer: applications in personalized medicine
Jin Sun Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Hazel M. Weir et al.
CANCER RESEARCH (2016)
Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3
Dorit Di Gioia et al.
CLINICA CHIMICA ACTA (2016)
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer
Chee Khoon Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Lyndsay N. Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER plus breast cancer
James D. Joseph et al.
ELIFE (2016)
The potential for liquid biopsies in the precision medical treatment of breast cancer
Victoria A. Forte et al.
Cancer Biology & Medicine (2016)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
E. Senkus et al.
ANNALS OF ONCOLOGY (2015)
An individual reference limit for 'early' diagnosis of metastatic breast cancer during postoperative follow-up
Andrea Nicolini et al.
BIOMARKERS IN MEDICINE (2015)
Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients
Petra Stieber et al.
CLINICA CHIMICA ACTA (2015)
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
Eleonor Olsson et al.
EMBO MOLECULAR MEDICINE (2015)
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader
Suzanne E. Wardell et al.
ENDOCRINE-RELATED CANCER (2015)
Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors
Scott D. Ramsey et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer
Rinath Jeselsohn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
F. Cardoso et al.
BREAST (2014)
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
M. J. Duffy et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus
Annelieke E. C. A. B. Willemsen et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Jeffrey B. Smerage et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up
Lynn N. Henry et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
Francois-Clement Bidard et al.
LANCET ONCOLOGY (2014)
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R. Labianca et al.
ANNALS OF ONCOLOGY (2013)
Follow-up tests to detect recurrent disease: Patient's reassurance or medical need?
Ian E. Smith et al.
BREAST (2013)
Use of Imaging and Biomarker Tests for Posttreatment Care of Early-Stage Breast Cancer Survivors
Erin E. Hahn et al.
CANCER (2013)
Plastin3 Is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition and Is Associated with Colorectal Cancer Prognosis
Takehiko Yokobori et al.
CANCER RESEARCH (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
Chantal Tse et al.
CANCER TREATMENT REVIEWS (2012)
Circulating tumour cells in non-metastatic breast cancer: a prospective study
Anthony Lucci et al.
LANCET ONCOLOGY (2012)
Detection of HER2 amplification in circulating free DNA in patients with breast cancer
K. Page et al.
BRITISH JOURNAL OF CANCER (2011)
Vimentin in cancer and its potential as a molecular target for cancer therapy
Arun Satelli et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
Shih-Chung Wu et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences
Luigi Mariani et al.
BIOMARKERS (2009)
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
Hyo Song Kim et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
Suhail M. Ali et al.
CANCER (2008)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Catharine M. Sturgeon et al.
CLINICAL CHEMISTRY (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Follow-up after curative resection of colorectal cancer: A meta-analysis
Joe J. Tjandra et al.
DISEASES OF THE COLON & RECTUM (2007)
Surveillance testing among survivors of early-stage breast cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer:: A validation study of the CellSearch system
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2007)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients
Marco Tampellini et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
R Bartsch et al.
BMC CANCER (2006)
Serum tumor markers in breast cancer: Are they of clinical value?
MJ Duffy
CLINICAL CHEMISTRY (2006)
Follow-up cost of breast cancer patients with localized disease after primary treatment: A randomized trial
R Kokko et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer
M Cristofanilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Tumor markers in breast cancer - European Group on Tumor Markers recommendations
R Molina et al.
TUMOR BIOLOGY (2005)
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer
G Bertelli et al.
ONCOLOGY (2005)
Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA
G Sölétormos et al.
EUROPEAN JOURNAL OF CANCER (2004)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Follow-up of patients with curatively resected colorectal cancer: a practice guideline
A Figueredo et al.
BMC CANCER (2003)
Ca 15-3 in the follow-up of localised breast cancer: a prospective study
R Kokko et al.
EUROPEAN JOURNAL OF CANCER (2002)
Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials
AG Renehan et al.
BMJ-BRITISH MEDICAL JOURNAL (2002)
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
RC Bast et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Tumour marker measurements in the diagnosis and monitoring of breast cancer
KL Cheung et al.
CANCER TREATMENT REVIEWS (2000)
Share Paper
